<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Extrapulmonary small cell cancer</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Extrapulmonary small cell cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Extrapulmonary small cell cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Donald C Doll, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rogerio C Lilenbaum, MD, FACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Small cell carcinoma is a distinct clinicopathologic entity that usually arises in the lung but can also originate in a wide range of extrapulmonary sites. Small cell carcinoma is the preferred terminology, but these tumors have also been referred to as oat cell carcinoma or sarcoma, small cell neuroendocrine carcinoma, small cell tumor, anaplastic cell carcinoma, microcytoma, reserve cell carcinoma, undifferentiated carcinoma, Kulchitsky cell carcinoma, and carcinoma with amine precursor uptake decarboxylation (APUD) cell differentiation. These tumors are thought to originate from totipotent stem cells present in all tissues, although some small cell carcinomas may arise from more well-differentiated tumors.</p><p>Extrapulmonary small cell carcinomas (ESCCs) are extremely rare; these tumors have been described most frequently in the urinary bladder, prostate, esophagus, stomach, colon and rectum, gallbladder, larynx, salivary glands, cervix, and skin. In addition, small cell carcinoma will occasionally present with metastatic disease, and a primary site cannot be identified (small cell carcinoma of unknown primary).</p><p>The diverse origin of these ESCCs is illustrated by a study of 120 patients, in which the site of origin was the female genital tract (26 percent), gastrointestinal tract (23 percent), genitourinary tract (19 percent), head and neck (16 percent), unknown primary site (13 percent), and other sites (4.3 percent) [<a href="#rid1">1</a>]. Similar findings have been reported by other groups [<a href="#rid2">2,3</a>].</p><p>Although extrapulmonary undifferentiated large cell neuroendocrine carcinomas are distinct histologically, the natural history of such lesions is similar to that of ESCC, and the treatment approach is the same. (See  <a class="medical medical_review" href="/z/d/html/4603.html" rel="external">"Pathology of lung malignancies", section on 'Large cell neuroendocrine carcinoma'</a>.)</p><p>The key features and general management of ESCCs will be reviewed here, followed by a discussion of ESCCs that arise in relatively more common sites. ESCCs arising in the tubular gastrointestinal tract and the pancreas, cervix, urinary bladder, and with an unknown primary are discussed separately, as is Merkel cell carcinoma of the skin, which is included in the differential diagnosis of these tumors.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/98796.html" rel="external">"High-grade gastroenteropancreatic neuroendocrine neoplasms"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13930.html" rel="external">"Small cell neuroendocrine carcinoma of the cervix"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2979.html" rel="external">"Small cell carcinoma of the bladder"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4876.html" rel="external">"Neuroendocrine neoplasms of unknown primary site"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7623.html" rel="external">"Pathogenesis, clinical features, and diagnosis of Merkel cell (neuroendocrine) carcinoma"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">OVERVIEW OF ESCC</span><span class="headingEndMark"> — </span>ESCCs have an aggressive natural history that is characterized by early, widespread metastases. Although some patients who present with locoregional disease may be cured by aggressive therapy, most relapse and the overall prognosis is poor, with less than 15 percent reaching five-year survival [<a href="#rid4">4</a>]. In different studies, the median survival for limited and extensive disease ranges from 1.4 to 3.5 years and 8 to 12 months, respectively [<a href="#rid1">1,2</a>].</p><p>Patients may have local relapse or distant metastases at relapse. In one series of 159 patients, 22 patients (13 percent) had local recurrence, 49 (31 percent) had distant metastases, and 20 (13 percent) had both local and distant disease [<a href="#rid5">5</a>]. The liver was the most common site of metastatic disease; only four patients (2.5 percent) had brain metastases at the time of first relapse.</p><p>The initial clinical manifestations are often due to locoregional disease, and the presenting symptoms may be indistinguishable from other tumors arising in the same site. ESCCs also can present with symptoms from distant metastases or with paraneoplastic syndromes, as occurs with small cell lung cancer (SCLC). (See  <a class="medical medical_review" href="/z/d/html/4641.html" rel="external">"Clinical manifestations of lung cancer", section on 'Paraneoplastic phenomena'</a>.)</p><p>A variety of laboratory abnormalities have been reported with ESCC. Immunohistochemistry for thyroid transcription factor 1 (TTF-1) in concert with synaptophysin may help to differentiate ESCC from poorly differentiated carcinomas [<a href="#rid6">6</a>]. As an example, paraneoplastic syndromes can result in hyponatremia, hypokalemia, or hypercalcemia, any of which may require specific treatment. Tumor-associated neuroendocrine markers have been elevated in some cases, although it is generally not useful to measure or monitor these proteins.</p><p>ESCCs have the same histologic appearance as SCLC regardless of their site of origin. In most cases, electron microscopy can identify neurosecretory granules that establish the neuroendocrine origin of the tumor, but the absence of such granules does not rule out ESCC. ESCCs are often found in conjunction with other tumor types, and the presence of a small cell component usually determines the biologic aggressiveness of a tumor. The histopathology of SCLC is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4603.html" rel="external">"Pathology of lung malignancies", section on 'Neuroendocrine tumors'</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Staging</span><span class="headingEndMark"> — </span>The initial evaluation of a patient with ESCC should include evaluation of the primary tumor and regional lymph nodes to assess the extent of locoregional disease, and computed tomography (CT) of the chest to rule out a primary SCLC.</p><p>Prior to treatment, patients should be evaluated to determine whether or not distant metastases are present. Positron emission tomography (PET) is useful in the staging and treatment response of ESCC and should be considered in the initial staging of such patients [<a href="#rid7">7</a>]. As an example, in one study of 33 patients with ESCC, PET scans influenced management in 19 percent of 43 imaging studies. Other imaging procedures that can be useful include abdominal and pelvic CT scans and bone scan.</p><p>Magnetic resonance imaging (MRI) of the brain is recommended if neurologic symptoms are present. Bone marrow biopsy is indicated only if there are abnormal blood counts or findings on the peripheral smear, without other evidence of disseminated disease. Based on the results of such evaluation, patients with disease confined to a primary site and/or regional nodes are classified as having limited disease, while all others are considered to have extensive disease.</p><p class="headingAnchor" id="H4"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>The initial management of patients with locoregional disease is patterned after that for other tumor types arising in the same extrapulmonary site. In general, this includes surgery and/or radiation therapy (RT) and chemotherapy. Despite aggressive locoregional treatment, relapse is common and adjuvant systemic chemotherapy is generally recommended. There are no randomized clinical trials or prospective clinical studies, and this approach is based upon case reports and extrapolation from the experience with SCLC. Most patients develop metastatic disease despite adjuvant therapy, and the prognosis is poor.</p><p>The treatment of systemic disease with chemotherapy is based upon that used in SCLC, typically a platinum-based regimen with <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>. Objective responses are common, but most are partial and of short duration [<a href="#rid8">8-10</a>]. Amrubicin monotherapy has been noted to be effective as salvage therapy after platinum-based chemotherapy [<a href="#rid11">11</a>]. However, <a class="drug drug_general" data-topicid="10007" href="/z/d/drug information/10007.html" rel="external">topotecan</a> shows only modest activity in pretreated ESCC [<a href="#rid12">12</a>]. However, immunotherapy has expanded the treatment for SCLC both in the front-line and relapse settings [<a href="#rid13">13-16</a>]. Anecdotal cases of immunotherapy in ESCC have been noted [<a href="#rid17">17-19</a>], and thus the role of immunotherapy in these rare tumors warrants further investigation. (See  <a class="medical medical_review" href="/z/d/html/4633.html" rel="external">"Extensive-stage small cell lung cancer: Initial management"</a> and  <a class="medical medical_review" href="/z/d/html/4614.html" rel="external">"Treatment of refractory and relapsed small cell lung cancer"</a>.)</p><p>The prognosis for patients with disseminated disease is poor despite chemotherapy and, in general, is similar to that for patients with extensive SCLC. However, two reports noted that patients with ESCC had a worse response rate, medial survival, and prognosis compared with patients with SCLC [<a href="#rid20">20</a>]. This may be especially true for patients with ESCC of the hepatobiliary tract and pancreas [<a href="#rid21">21</a>] and those with poor performance status and liver involvement [<a href="#rid20">20</a>]. By contrast, in another series patients with ESCC had a better three-year survival than those with SCLC (19 versus 5 percent) [<a href="#rid3">3</a>]. Breast ESCC had the best three-year survival (60 percent) and gastrointestinal the worst (7 percent). The choice of chemotherapy regimen, duration of treatment, role of maintenance therapy, and retreatment following relapse in patients are discussed elsewhere.</p><p>In general, prophylactic cranial irradiation is not recommended because there appears to be a decreased incidence of brain metastases in ESCC compared with SCLC [<a href="#rid1">1,4</a>]. In a review of 280 patients with ESCC treated over a 12-year period, only 18 patients (6 percent) developed brain metastases [<a href="#rid22">22</a>]. However, prostate and head and neck ESCC have been reported to have a higher frequency of brain metastases; 16 to 19 percent and 41 percent, respectively. Thus, prophylactic cranial radiation can be considered in such patients [<a href="#rid23">23,24</a>].</p><p class="headingAnchor" id="H6"><span class="h1">PROSTATE ESCC</span><span class="headingEndMark"> — </span>Pure ESCC arising in the prostate is a rare disorder that is distinct from the far more common prostatic adenocarcinoma. Guidelines from the National Comprehensive Cancer Network (NCCN) suggest a combination of <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> with either <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> in patients with pure small cell carcinoma of the prostate; or the combination of <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> and carboplatin [<a href="#rid25">25</a>].</p><p>Prostate cancer with neuroendocrine features (termed aggressive-variant prostate cancer) may also emerge during the progression of prostate cancer. The optimal way to manage men with castration-resistant, metastatic prostate cancer and neuroendocrine differentiation is not established. However, patients may be sensitive to chemotherapy regimens containing a taxane and platinum agent, which is discussed in more detail elsewhere. Immunotherapy has also been used for platinum-resistant ESCC of the prostate [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/z/d/html/6945.html" rel="external">"Chemotherapy in advanced castration-resistant prostate cancer", section on 'Aggressive prostate cancer variants'</a>.) </p><p class="headingAnchor" id="H3103824542"><span class="h1">GALLBLADDER ESCC</span><span class="headingEndMark"> — </span>ESCC accounts for between 1 and 5 percent of malignancies arising in the gallbladder [<a href="#rid26">26</a>]. The epidemiology of gallbladder ESCC is similar to that of adenocarcinoma, suggesting common etiologic factors [<a href="#rid27">27-29</a>]. In a series of 53 patients, small cell carcinoma was twice as common in women, the median age at diagnosis was 64 years, and two-thirds had coexisting cholelithiasis [<a href="#rid27">27</a>]. (See  <a class="medical medical_review" href="/z/d/html/2491.html" rel="external">"Gallbladder cancer: Epidemiology, risk factors, clinical features, and diagnosis"</a>.)</p><p>Patients typically present with a large tumor mass that is indistinguishable from other tumors arising in the gallbladder. The symptoms and findings on physical examination are secondary to the presence of a mass or obstruction of the biliary tract [<a href="#rid27">27,30</a>]. In addition, gallbladder ESCC may be associated with paraneoplastic syndromes. Laboratory features are nonspecific and reflect obstruction of the biliary tract. (See  <a class="medical medical_review" href="/z/d/html/2491.html" rel="external">"Gallbladder cancer: Epidemiology, risk factors, clinical features, and diagnosis"</a>.)</p><p>The microscopic findings are similar to those of small cell lung cancer (SCLC). In some cases, ESCC is found in conjunction with adenocarcinoma or other histologic types of gallbladder cancer [<a href="#rid26">26</a>]. Tumors with mixed histology are consistent with the hypothesis that ESCC arises either from a totipotent stem cell or within foci of more differentiated tumors. (See  <a class="medical medical_review" href="/z/d/html/4603.html" rel="external">"Pathology of lung malignancies", section on 'Neuroendocrine tumors'</a>.)</p><p>Abdominal ultrasound is the preferred imaging modality for biliary tract disease. The mass may obstruct the biliary tree as well as the vessels of porta hepatis [<a href="#rid27">27</a>]. Computed tomography (CT), endoscopic retrograde cholangiopancreatography (ERCP), and angiography can also be useful in staging and treatment planning, although laparotomy is often required to obtain tissue for a diagnosis and define the extent of disease [<a href="#rid27">27</a>].</p><p>Prior to treatment, patients should be evaluated to rule out a primary SCLC or evidence of distant metastases (see <a class="local">'Overview of ESCC'</a> above). There is no specific staging system for gallbladder ESCC; tumors should be staged according to the Tumor, Node, Metastasis (TNM) system  (<a class="graphic graphic_table graphicRef110890" href="/z/d/graphic/110890.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/2491.html" rel="external">"Gallbladder cancer: Epidemiology, risk factors, clinical features, and diagnosis", section on 'TNM staging system'</a>.).</p><p class="headingAnchor" id="H737132087"><span class="h2">Treatment and prognosis</span><span class="headingEndMark"> — </span>Almost all gallbladder ESCCs are either locally advanced or metastatic at diagnosis, and the prognosis is poor [<a href="#rid26">26-29</a>]. In a series of 53 cases from the literature, those with disseminated disease had a median survival of eight months, and one- and two-year survival rates of 28 and 0 percent, respectively [<a href="#rid27">27</a>].</p><p>In patients with localized disease, surgical resection may result in prolonged survival in occasional patients [<a href="#rid31">31</a>]. However, the development of distant metastases in most patients has led to the use of systemic chemotherapy as adjuvant therapy in this setting [<a href="#rid27">27</a>].</p><p>Chemotherapy is also used in the treatment for disseminated disease. Although there are no clinical trials of different regimens, the choice of systemic therapy is based upon the experience in SCLC. (See  <a class="medical medical_review" href="/z/d/html/4633.html" rel="external">"Extensive-stage small cell lung cancer: Initial management"</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">LARYNGEAL ESCC</span><span class="headingEndMark"> — </span>ESCC can arise anywhere in the head-neck region and occurs most frequently in the larynx [<a href="#rid32">32-35</a>]. The epidemiology and risk factors for laryngeal ESCC are similar to that for other laryngeal tumors. Most patients are between the ages of 60 and 80, and there is a slight male predominance [<a href="#rid32">32</a>]. Smoking, chewing tobacco, and excess alcohol intake have been associated with ESCC of the larynx [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/z/d/html/3390.html" rel="external">"Epidemiology and risk factors for head and neck cancer", section on 'Risk factors'</a>.)</p><p>The clinical features of laryngeal ESCC are similar to those of other laryngeal tumors and are due to the presence of a laryngeal mass [<a href="#rid32">32</a>]. Cervical lymph node metastases are often the initial site of tumor spread, and the origin of the tumor in the larynx only becomes apparent when the patient later presents with hoarseness [<a href="#rid36">36</a>]. In a review of 66 cases, cervical lymph node involvement was present in 35 (53 percent) at presentation [<a href="#rid32">32</a>]. In addition, some patients have symptoms from paraneoplastic syndromes. (See  <a class="medical medical_review" href="/z/d/html/3393.html" rel="external">"Overview of the diagnosis and staging of head and neck cancer"</a>.)</p><p>ESCC of the larynx grossly is indistinguishable from other tumors [<a href="#rid32">32</a>], while its histopathologic appearance is the same as that of small cell lung cancer (SCLC). In addition to small cell carcinoma, large cell poorly differentiated neuroendocrine tumors have been described [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/z/d/html/4603.html" rel="external">"Pathology of lung malignancies", section on 'Neuroendocrine tumors'</a>.)</p><p>Although most tumors are composed of pure ESCC, some have elements of squamous cell carcinoma or adenocarcinoma [<a href="#rid36">36-39</a>]. These composite tumors are thought to arise in a common totipotent stem cell that can differentiate into various cell types.</p><p>The differentiation of ESCC from other laryngeal tumors requires biopsy and histologic examination of the tumor. Tissue may be obtained from the tumor itself or from a cervical lymph node.</p><p>Before treatment, patients should be evaluated to rule out primary SCLC or evidence of distant metastases, which are often present at diagnosis (see <a class="local">'Overview of ESCC'</a> above). Laryngeal small cell carcinoma is staged according to the Tumor, Node, Metastasis (TNM) staging classification used for squamous cell carcinoma of the larynx  (<a class="graphic graphic_table graphicRef110769" href="/z/d/graphic/110769.html" rel="external">table 2</a>). (See <a class="local">'Staging'</a> above.)</p><p class="headingAnchor" id="H17"><span class="h2">Treatment and prognosis</span><span class="headingEndMark"> — </span>The overall prognosis of ESCC of the larynx is poor due to early spread of disease, with a five-year disease-specific survival rate of less than 20 percent [<a href="#rid35">35</a>].</p><p>In patients without distant metastases, management of local and regional disease has relied upon surgery, radiation therapy (RT), or a combined-modality approach [<a href="#rid36">36,38</a>]. Although occasional long-term survivors have been reported [<a href="#rid33">33</a>], the local recurrence rate is high, especially when disease is present in the cervical lymph nodes, and distant metastases are almost always seen. (See  <a class="medical medical_review" href="/z/d/html/3402.html" rel="external">"Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The larynx and hypopharynx"</a>.)</p><p>Systemic chemotherapy, used as an adjuvant following local treatment and for the management of patients who present with metastatic disease, may induce remissions and prolong survival [<a href="#rid35">35</a>]. The chemotherapy approach is the same as that used for extensive SCLC (see  <a class="medical medical_review" href="/z/d/html/4633.html" rel="external">"Extensive-stage small cell lung cancer: Initial management"</a>). However, because of the low incidence of central nervous system (CNS) metastases in patients with ESCC of the larynx, prophylactic cranial radiation is not recommended [<a href="#rid40">40</a>].</p><p>In patients with metastatic disease, control of laryngeal disease can take precedence over systemic treatment if there is an imminent risk of respiratory obstruction. In such situations, RT is preferred followed by systemic chemotherapy [<a href="#rid41">41</a>].</p><p class="headingAnchor" id="H18"><span class="h1">SALIVARY GLAND ESCC</span><span class="headingEndMark"> — </span>ESCCs of the parotid, submandibular, and minor salivary glands account for 1 to 2 percent of all salivary gland tumors [<a href="#rid42">42</a>]. There are no known risk factors for ESCC of the salivary glands. Most tumors occur between the ages of 50 and 70 years.</p><p>The typical patient presents with a rapidly growing, painless mass in a salivary gland [<a href="#rid43">43</a>]. Less often, pain may be noted and some patients may present with symptoms due to a paraneoplastic syndrome.</p><p>The histologic appearance of salivary gland ESCC is similar to that of small cell lung cancer (SCLC). In addition to pure ESCC, tumors with concurrent features of squamous or ductal differentiation have been described [<a href="#rid44">44,45</a>]. Salivary gland ESCC appears to arise from stem cells of the salivary duct system capable of differentiation to ductal or neuroendocrine-like cells [<a href="#rid44">44</a>]. (See  <a class="medical medical_review" href="/z/d/html/3400.html" rel="external">"Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging"</a>.)</p><p>The diagnosis is based upon histologic examination of a biopsy sample, from either a fine-needle aspirate or a surgical resection specimen. Before treatment, patients should be evaluated to rule out a primary SCLC or evidence of distant metastases (see <a class="local">'Overview of ESCC'</a> above). There is no separate staging classification for ESCC of the salivary glands, and these tumors are staged according to the Tumor, Node, Metastasis (TNM) system  (<a class="graphic graphic_table graphicRef110657" href="/z/d/graphic/110657.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef110617" href="/z/d/graphic/110617.html" rel="external">table 4</a>) [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H19"><span class="h2">Treatment and prognosis</span><span class="headingEndMark"> — </span>Decisions regarding therapy are largely based upon experience with other salivary gland tumors and anecdotal case reports. For patients who present without evidence of metastatic disease, surgical resection of the tumor, along with regional lymph node dissection, is the preferred treatment. Postoperative radiation therapy (RT) has been used to improve local control, although there are no trials documenting its efficacy.</p><p>Despite local treatment, most patients relapse with distant disease. Adjuvant systemic chemotherapy has been used with platinum-based regimens. Metastatic disease, whether present at diagnosis or developing after treatment of the primary tumor, is managed with systemic therapy. Systemic therapy regimens are based upon those used for patients with SCLC. (See  <a class="medical medical_review" href="/z/d/html/4633.html" rel="external">"Extensive-stage small cell lung cancer: Initial management"</a>.)</p><p>When compared with ESCCs arising in the larynx and other sites, those originating in salivary glands appear to have a better prognosis. In a retrospective analysis of 20 patients, the two- and five-year survival rates were 70 and 46 percent, respectively, compared with 16 and 5 percent for laryngeal small cell carcinoma [<a href="#rid44">44</a>]. This may be due to early recognition of salivary gland abnormalities because of their superficial location, thereby permitting earlier diagnosis.</p><p class="headingAnchor" id="H20"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Introduction</strong> – Small cell carcinoma is a distinct clinicopathologic entity that usually arises in the lung but can also originate in a wide range of extrapulmonary sites. These tumors are thought to originate from totipotent stem cells present in all tissues, although some small cell carcinomas may arise from more well-differentiated tumors. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Extrapulmonary small cell carcinomas (ESCCs) are extremely rare; these tumors have been described most frequently in the urinary bladder, prostate, esophagus, stomach, colon and rectum, gallbladder, larynx, salivary glands, cervix, and skin. (See <a class="local">'Overview of ESCC'</a> above.)</p><p></p><p class="bulletIndent1">Although the initial clinical manifestations are often due to locoregional disease, ESCCs have an aggressive natural history that is characterized by early, widespread metastases. Although some patients who present with locoregional disease may be cured by aggressive therapy, most relapse and the overall prognosis is poor. (See <a class="local">'Overview of ESCC'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Staging</strong> – The initial evaluation of patients with ESCCs should include evaluation of the primary tumor and regional lymph nodes to assess the extent of locoregional disease and computed tomography (CT) of the chest to rule out a primary small cell lung cancer (SCLC). Prior to treatment, patients should be evaluated to determine whether or not distant metastases are present. (See <a class="local">'Staging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – The initial management of patients with locoregional disease is patterned after that for other tumor types arising in the same extrapulmonary site. Despite aggressive locoregional treatment, relapse is common and adjuvant systemic chemotherapy is generally recommended, although all data are derived from case reports and no randomized clinical trials have been conducted. Despite adjuvant therapy, most patients develop metastatic disease. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1">The management of systemic disease with chemotherapy is patterned after the approach used in SCLC and generally utilizes a combination of a platinum compound and <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>. Although objective responses are commonly observed, most are partial and of short duration. (See  <a class="medical medical_review" href="/z/d/html/4633.html" rel="external">"Extensive-stage small cell lung cancer: Initial management"</a>.)</p><p></p><p class="headingAnchor" id="H2830853542"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Nasir Shahab, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Brennan SM, Gregory DL, Stillie A, et al. Should extrapulmonary small cell cancer be managed like small cell lung cancer? Cancer 2010; 116:888.</a></li><li><a class="nounderline abstract_t">Ochsenreither S, Marnitz-Schultze S, Schneider A, et al. Extrapulmonary small cell carcinoma (EPSCC): 10 years' multi-disciplinary experience at Charité. Anticancer Res 2009; 29:3411.</a></li><li><a class="nounderline abstract_t">Wong YN, Jack RH, Mak V, et al. The epidemiology and survival of extrapulmonary small cell carcinoma in South East England, 1970-2004. BMC Cancer 2009; 9:209.</a></li><li><a class="nounderline abstract_t">Walenkamp AM, Sonke GS, Sleijfer DT. Clinical and therapeutic aspects of extrapulmonary small cell carcinoma. Cancer Treat Rev 2009; 35:228.</a></li><li><a class="nounderline abstract_t">Gennatas S, Noble J, Stanway S, et al. Patterns of relapse in extrapulmonary small cell carcinoma: retrospective analysis of outcomes from two cancer centres. BMJ Open 2015; 5:e006440.</a></li><li><a class="nounderline abstract_t">Quinn AM, Blackhall F, Wilson G, et al. Extrapulmonary small cell carcinoma: a clinicopathological study with identification of potential diagnostic mimics. Histopathology 2012; 61:454.</a></li><li><a class="nounderline abstract_t">Gregory DL, Brennan SM, Stillie A, et al. Impact of 18F-fluorodeoxyglucose positron emission tomography in the staging and treatment response assessment of extra-pulmonary small-cell cancer. J Med Imaging Radiat Oncol 2010; 54:100.</a></li><li><a class="nounderline abstract_t">Kim JH, Lee SH, Park J, et al. Extrapulmonary small-cell carcinoma: a single-institution experience. Jpn J Clin Oncol 2004; 34:250.</a></li><li><a class="nounderline abstract_t">Sengoz M, Abacioglu U, Salepci T, et al. Extrapulmonary small cell carcinoma: multimodality treatment results. Tumori 2003; 89:274.</a></li><li><a class="nounderline abstract_t">Soto DE, Eisbruch A. Limited-stage extrapulmonary small cell carcinoma: outcomes after modern chemotherapy and radiotherapy. Cancer J 2007; 13:243.</a></li><li><a class="nounderline abstract_t">Nio K, Arita S, Isobe T, et al. Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy. Cancer Chemother Pharmacol 2015; 75:829.</a></li><li><a class="nounderline abstract_t">Apostolidis L, Bergmann F, Jäger D, Winkler EC. Efficacy of topotecan in pretreated metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma. Cancer Med 2016; 5:2261.</a></li><li><a class="nounderline abstract_t">Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 2016; 17:883.</a></li><li><a class="nounderline abstract_t">Ott PA, Elez E, Hiret S, et al. Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study. J Clin Oncol 2017; 35:3823.</a></li><li><a class="nounderline abstract_t">Horn L, Mansfield AS, Szczęsna A, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med 2018; 379:2220.</a></li><li><a class="nounderline abstract_t">Rossi A. Immunotherapy in small cell lung cancer. EMJ 2019; 4:43.</a></li><li><a class="nounderline abstract_t">Ugwu JK, Nwanyanwu C, Shelke AR. Dramatic Response of a Metastatic Primary Small-Cell Carcinoma of the Pancreas to a Trial of Immunotherapy with Nivolumab: A Case Report. Case Rep Oncol 2017; 10:720.</a></li><li><a class="nounderline abstract_t">Husnain M, Park W, Ramos JC, et al. Complete response to ipilimumab and nivolumab therapy in a patient with extensive extrapulmonary high-grade small cell carcinoma of the pancreas and HIV infection. J Immunother Cancer 2018; 6:66.</a></li><li><a class="nounderline abstract_t">Salhab M, Donahue M, Walsh W. Pembrolizumab for platinum-refractory small cell carcinoma of the prostate, case report. Hematol Med Oncol 2018.</a></li><li><a class="nounderline abstract_t">Terashima T, Morizane C, Hiraoka N, et al. Comparison of chemotherapeutic treatment outcomes of advanced extrapulmonary neuroendocrine carcinomas and advanced small-cell lung carcinoma. Neuroendocrinology 2012; 96:324.</a></li><li><a class="nounderline abstract_t">Iwasa S, Morizane C, Okusaka T, et al. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. Jpn J Clin Oncol 2010; 40:313.</a></li><li><a class="nounderline abstract_t">Naidoo J, Teo MY, Deady S, et al. Should patients with extrapulmonary small-cell carcinoma receive prophylactic cranial irradiation? J Thorac Oncol 2013; 8:1215.</a></li><li><a class="nounderline abstract_t">Yazıcı O, Ozdemir NY, Sendur MA, et al. Current approaches for prophylactic cranial irradiation in extrapulmonary small cell carcinoma. Curr Med Res Opin 2014; 30:1327.</a></li><li><a class="nounderline abstract_t">De Felice F, Lei M, Guerrero Urbano T. Controversies in small cell carcinoma of the head and neck: Prophylactic cranial irradiation (PCI) after primary complete initial remission. Cancer Treat Rev 2015; 41:725.</a></li><li class="breakAll">National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Prostate cancer. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (Accessed on September 17, 2019).</li><li><a class="nounderline abstract_t">Albores-Saavedra J, Soriano J, Larraza-Hernandez O, et al. Oat cell carcinoma of the gallbladder. Hum Pathol 1984; 15:639.</a></li><li><a class="nounderline abstract_t">Fujii H, Aotake T, Horiuchi T, et al. Small cell carcinoma of the gallbladder: a case report and review of 53 cases in the literature. Hepatogastroenterology 2001; 48:1588.</a></li><li><a class="nounderline abstract_t">Maitra A, Tascilar M, Hruban RH, et al. Small cell carcinoma of the gallbladder: a clinicopathologic, immunohistochemical, and molecular pathology study of 12 cases. Am J Surg Pathol 2001; 25:595.</a></li><li><a class="nounderline abstract_t">Moskal TL, Zhang PJ, Nava HR. Small cell carcinoma of the gallbladder. J Surg Oncol 1999; 70:54.</a></li><li><a class="nounderline abstract_t">Albores-Saavedra J, Cruz-Ortiz H, Alcantara-Vazques A, Henson DE. Unusual types of gallbladder carcinoma. A report of 16 cases. Arch Pathol Lab Med 1981; 105:287.</a></li><li><a class="nounderline abstract_t">Matsuo S, Shinozaki T, Yamaguchi S, et al. Small-cell carcinoma of the gallbladder: report of a case. Surg Today 2000; 30:89.</a></li><li><a class="nounderline abstract_t">Ferlito A. Diagnosis and treatment of small cell carcinoma of the larynx: a critical review. Ann Otol Rhinol Laryngol 1986; 95:590.</a></li><li><a class="nounderline abstract_t">Gnepp DR, Ferlito A, Hyams V. Primary anaplastic small cell (oat cell) carcinoma of the larynx. Review of the literature and report of 18 cases. Cancer 1983; 51:1731.</a></li><li><a class="nounderline abstract_t">Ferlito A, Barnes L, Rinaldo A, et al. A review of neuroendocrine neoplasms of the larynx: update on diagnosis and treatment. J Laryngol Otol 1998; 112:827.</a></li><li><a class="nounderline abstract_t">van der Laan TP, Plaat BE, van der Laan BF, Halmos GB. Clinical recommendations on the treatment of neuroendocrine carcinoma of the larynx: A meta-analysis of 436 reported cases. Head Neck 2015; 37:707.</a></li><li><a class="nounderline abstract_t">Mills SE, Cooper PH, Garland TA, Johns ME. Small cell undifferentiated carcinoma of the larynx. Report of two patients and review of 13 additional cases. Cancer 1983; 51:116.</a></li><li><a class="nounderline abstract_t">Gianoli GJ, Butcher RB, Martin EJ 3rd. Composite tumor of the larynx. Ear Nose Throat J 1992; 71:81.</a></li><li><a class="nounderline abstract_t">Pardo Mindán FJ, Algarra SM, Lozano BR, Tapia RG. Oat cell carcinoma of the larynx. A study of six new cases. Histopathology 1989; 14:75.</a></li><li><a class="nounderline abstract_t">Ferlito A. Double primary synchronous and metachronous cancer of the larynx and hypopharynx with dissimilar histology. Five case reports and review of the literature. Arch Otorhinolaryngol 1980; 229:107.</a></li><li><a class="nounderline abstract_t">Coca-Pelaz A, Devaney KO, Rodrigo JP, et al. Should patients with laryngeal small cell neuroendocrine carcinoma receive prophylactic cranial irradiation? Eur Arch Otorhinolaryngol 2016; 273:2925.</a></li><li><a class="nounderline abstract_t">Aguilar EA 3rd, Robbins KT, Stephens J, et al. Primary oat cell carcinoma of the larynx. Am J Clin Oncol 1987; 10:26.</a></li><li><a class="nounderline abstract_t">Nagao K, Matsuzaki O, Saiga H, et al. Histopathologic studies of undifferentiated carcinoma of the parotid gland. Cancer 1982; 50:1572.</a></li><li><a class="nounderline abstract_t">Kraemer BB, Mackay B, Batsakis JG. Small cell carcinomas of the parotid gland. A clinicopathologic study of three cases. Cancer 1983; 52:2115.</a></li><li><a class="nounderline abstract_t">Gnepp DR, Wick MR. Small cell carcinoma of the major salivary glands. An immunohistochemical study. Cancer 1990; 66:185.</a></li><li><a class="nounderline abstract_t">Hui KK, Luna MA, Batsakis JG, et al. Undifferentiated carcinomas of the major salivary glands. Oral Surg Oral Med Oral Pathol 1990; 69:76.</a></li><li class="breakAll">Salivary gland. In: American Joint Committee on Cancer Staging Manual, Edge SB, Byrd DR, Compton CC, et al (Eds), Spring, New York 2009. p.79.</li></ol></div><div id="topicVersionRevision">Topic 4882 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20052730" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Should extrapulmonary small cell cancer be managed like small cell lung cancer?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19661365" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Extrapulmonary small cell carcinoma (EPSCC): 10 years' multi-disciplinary experience at Charité.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19563623" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The epidemiology and survival of extrapulmonary small cell carcinoma in South East England, 1970-2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19068273" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical and therapeutic aspects of extrapulmonary small cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25588780" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Patterns of relapse in extrapulmonary small cell carcinoma: retrospective analysis of outcomes from two cancer centres.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22687056" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Extrapulmonary small cell carcinoma: a clinicopathological study with identification of potential diagnostic mimics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20518871" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Impact of 18F-fluorodeoxyglucose positron emission tomography in the staging and treatment response assessment of extra-pulmonary small-cell cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15231859" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Extrapulmonary small-cell carcinoma: a single-institution experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12908782" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Extrapulmonary small cell carcinoma: multimodality treatment results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17762759" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Limited-stage extrapulmonary small cell carcinoma: outcomes after modern chemotherapy and radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25702050" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27456539" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Efficacy of topotecan in pretreated metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27269741" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28813164" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30280641" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Immunotherapy in small cell lung cancer</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28878656" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Dramatic Response of a Metastatic Primary Small-Cell Carcinoma of the Pancreas to a Trial of Immunotherapy with Nivolumab: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29986769" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Complete response to ipilimumab and nivolumab therapy in a patient with extensive extrapulmonary high-grade small cell carcinoma of the pancreas and HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pembrolizumab for platinum-refractory small cell carcinoma of the prostate, case report</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22572060" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Comparison of chemotherapeutic treatment outcomes of advanced extrapulmonary neuroendocrine carcinomas and advanced small-cell lung carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20047862" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23945390" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Should patients with extrapulmonary small-cell carcinoma receive prophylactic cranial irradiation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24628530" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Current approaches for prophylactic cranial irradiation in extrapulmonary small cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26211602" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Controversies in small cell carcinoma of the head and neck: Prophylactic cranial irradiation (PCI) after primary complete initial remission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26211602" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Controversies in small cell carcinoma of the head and neck: Prophylactic cranial irradiation (PCI) after primary complete initial remission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6086490" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Oat cell carcinoma of the gallbladder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11813580" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Small cell carcinoma of the gallbladder: a case report and review of 53 cases in the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11342770" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Small cell carcinoma of the gallbladder: a clinicopathologic, immunohistochemical, and molecular pathology study of 12 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9989422" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Small cell carcinoma of the gallbladder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6263212" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Unusual types of gallbladder carcinoma. A report of 16 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10648093" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Small-cell carcinoma of the gallbladder: report of a case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3024550" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Diagnosis and treatment of small cell carcinoma of the larynx: a critical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6299507" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Primary anaplastic small cell (oat cell) carcinoma of the larynx. Review of the literature and report of 18 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9876371" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A review of neuroendocrine neoplasms of the larynx: update on diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24596175" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Clinical recommendations on the treatment of neuroendocrine carcinoma of the larynx: A meta-analysis of 436 reported cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6295589" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Small cell undifferentiated carcinoma of the larynx. Report of two patients and review of 13 additional cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1315242" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Composite tumor of the larynx.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2538387" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Oat cell carcinoma of the larynx. A study of six new cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6257215" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Double primary synchronous and metachronous cancer of the larynx and hypopharynx with dissimilar histology. Five case reports and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26530293" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Should patients with laryngeal small cell neuroendocrine carcinoma receive prophylactic cranial irradiation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3030091" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Primary oat cell carcinoma of the larynx.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6288218" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Histopathologic studies of undifferentiated carcinoma of the parotid gland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6313180" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Small cell carcinomas of the parotid gland. A clinicopathologic study of three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1693875" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Small cell carcinoma of the major salivary glands. An immunohistochemical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2296451" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Undifferentiated carcinomas of the major salivary glands.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
